NASDAQ:RDNT - RadNet Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $14.01 -0.21 (-1.48 %) (As of 02/19/2019 04:00 PM ET)Previous Close$14.22Today's Range$13.95 - $14.3552-Week Range$9.90 - $16.54Volume99,800 shsAverage Volume178,645 shsMarket Capitalization$684.61 millionP/E Ratio48.31Dividend YieldN/ABeta1.19 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems for the imaging industry, including picture archiving communications systems; and provides teleradiology services for remote interpretation of images on behalf of radiology groups, hospitals, and imaging center customers. As of December 31, 2017, it operated 297 facilities directly or indirectly through joint ventures with hospitals in California, Delaware, Florida, Maryland, New Jersey, and New York. The company was founded in 1981 and is headquartered in Los Angeles, California. Receive RDNT News and Ratings via Email Sign-up to receive the latest news and ratings for RDNT and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RDNT Previous Symbol CUSIPN/A Webwww.radnet.com Phone310-478-7808Debt Debt-to-Equity Ratio4.56 Current Ratio1.12 Quick Ratio1.12Price-To-Earnings Trailing P/E Ratio48.31 Forward P/E Ratio56.04 P/E Growth3.29 Sales & Book Value Annual Sales$922.19 million Price / Sales0.74 Cash Flow$1.8031 per share Price / Cash Flow7.77 Book Value$1.47 per share Price / Book9.53Profitability EPS (Most Recent Fiscal Year)$0.29 Net Income$50,000.00 Net Margins-0.44% Return on Equity14.62% Return on Assets1.75%Miscellaneous Employees7,300 Outstanding Shares48,866,000Market Cap$684.61 million OptionableOptionable RadNet (NASDAQ:RDNT) Frequently Asked Questions What is RadNet's stock symbol? RadNet trades on the NASDAQ under the ticker symbol "RDNT." How were RadNet's earnings last quarter? RadNet Inc. (NASDAQ:RDNT) announced its earnings results on Thursday, August, 9th. The medical research company reported $0.11 EPS for the quarter, missing analysts' consensus estimates of $0.13 by $0.02. The medical research company earned $244.40 million during the quarter, compared to analysts' expectations of $239.34 million. RadNet had a negative net margin of 0.44% and a positive return on equity of 14.62%. RadNet's quarterly revenue was up 6.3% on a year-over-year basis. During the same period in the previous year, the company posted $0.11 earnings per share. View RadNet's Earnings History. When is RadNet's next earnings date? RadNet is scheduled to release their next quarterly earnings announcement on Thursday, March 14th 2019. View Earnings Estimates for RadNet. What price target have analysts set for RDNT? 3 brokerages have issued 12 month target prices for RadNet's stock. Their forecasts range from $14.00 to $15.00. On average, they anticipate RadNet's stock price to reach $14.6667 in the next twelve months. This suggests a possible upside of 4.7% from the stock's current price. View Analyst Price Targets for RadNet. What is the consensus analysts' recommendation for RadNet? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for RadNet in the last year. There are currently 1 buy rating and 2 strong buy ratings for the stock, resulting in a consensus recommendation of "Strong Buy." View Analyst Ratings for RadNet. Has RadNet been receiving favorable news coverage? Media coverage about RDNT stock has trended somewhat positive recently, according to InfoTrie Sentiment. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. RadNet earned a daily sentiment score of 0.9 on InfoTrie's scale. They also gave news headlines about the medical research company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near term. Who are some of RadNet's key competitors? Some companies that are related to RadNet include InVitae (NVTA), CareDx (CDNA), Natera (NTRA), Veracyte (VCYT), Celcuity (CELC), Enzo Biochem (ENZ), Psychemedics (PMD), PotNetwork (POTN), Miragen Therapeutics (MGEN), Fulgent Genetics (FLGT), First Choice Healthcare Solutions (FCHS), OpGen (OPGN), CBA Florida (CBAI), Cancer Genetics (CGIX) and Aeon Global Health (AGHC). Who are RadNet's key executives? RadNet's management team includes the folowing people: Dr. Howard G. Berger, Chairman, Pres, CEO & Treasurer (Age 73)Mr. Mark D. Stolper, Exec. VP & CFO (Age 48)Mr. Norman R. Hames, Pres, COO of Western Operations & Director (Age 63)Mr. Stephen M. Forthuber, Pres & COO of Eastern Operations (Age 58)Mr. Ranjan Jayanathan, Chief Information Officer & GM of Radiology Information Technology Division Who are RadNet's major shareholders? RadNet's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Moab Capital Partners LLC (6.90%), BlackRock Inc. (6.57%), Dimensional Fund Advisors LP (3.24%), Geode Capital Management LLC (1.62%), Robotti Robert (1.33%) and Phoenician Capital LLC (1.23%). Company insiders that own RadNet stock include David L Swartz, Jeffrey L Linden, John V Crues, Lawrence L Levitt, Mark Stolper, Marvin S Cadwell, Michael L Md Sherman, Michael N Murdock, Norman R Hames, Sandy Nyholm Kaminsky and Stephen M Forthuber. View Institutional Ownership Trends for RadNet. Which institutional investors are selling RadNet stock? RDNT stock was sold by a variety of institutional investors in the last quarter, including Eqis Capital Management Inc., Robotti Robert, Two Sigma Investments LP, Mackay Shields LLC, Assenagon Asset Management S.A., State Board of Administration of Florida Retirement System, ClariVest Asset Management LLC and Squarepoint Ops LLC. Company insiders that have sold RadNet company stock in the last year include Jeffrey L Linden, John V Crues, Mark Stolper, Marvin S Cadwell, Michael N Murdock and Norman R Hames. View Insider Buying and Selling for RadNet. Which institutional investors are buying RadNet stock? RDNT stock was acquired by a variety of institutional investors in the last quarter, including Moab Capital Partners LLC, Phoenician Capital LLC, Global Alpha Capital Management Ltd., Royce & Associates LP, BlackRock Inc., Zacks Investment Management, Millennium Management LLC and Geode Capital Management LLC. View Insider Buying and Selling for RadNet. How do I buy shares of RadNet? Shares of RDNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is RadNet's stock price today? One share of RDNT stock can currently be purchased for approximately $14.01. How big of a company is RadNet? RadNet has a market capitalization of $684.61 million and generates $922.19 million in revenue each year. The medical research company earns $50,000.00 in net income (profit) each year or $0.29 on an earnings per share basis. RadNet employs 7,300 workers across the globe. What is RadNet's official website? The official website for RadNet is http://www.radnet.com. How can I contact RadNet? RadNet's mailing address is 1510 COTNER AVE, LOS ANGELES CA, 90025. The medical research company can be reached via phone at 310-478-7808 or via email at [email protected] MarketBeat Community Rating for RadNet (NASDAQ RDNT)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 233 (Vote Outperform)Underperform Votes: 208 (Vote Underperform)Total Votes: 441MarketBeat's community ratings are surveys of what our community members think about RadNet and other stocks. Vote "Outperform" if you believe RDNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RDNT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/19/2019 by MarketBeat.com StaffFeatured Article: What is the return on assets formula?